JAVELIN Bladder 100.

Pembrolizumab is the go-to second-line therapy for advanced bladder cancer after failing first-line platinum therapy. But there’s an ongoing push for “switch maintenance” therapy where immunotherapy is given immediately after platinum chemo without waiting for progression. In JAVELIN Bladder 100, the switch was tp maintenance avelumab. Once again investors couldn’t wait for ASCO, so we already know that maintenance avelumab significantly improved overall survival compared to observation.The Betting Line: Maintenance avelumab after platinum chemo significantly prolongs survival for advanced bladder cancer, and we may see this switch approach catch fire across other disease sites. | Powles, ASCO 2020


Popular Posts